Xsphera Biosciences utilizes an ex vivo platform that integrates human tissue samples with microfluidic devices to study tumor microenvironments and evaluate therapeutic responses. This approach addresses the limitations of in vivo testing by providing more accurate predictions of drug efficacy, thereby reducing clinical trial failure rates.
Funding
$12.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods of studying tumor microenvironments and evaluating therapeutic responses often fall short, with in vivo testing not always accurately predicting drug efficacy and leading to high clinical trial failure rates. Traditional approaches lack the ability to fully replicate the complexities of human tissue.
Solution
Xsphera Biosciences offers an ex vivo platform that integrates human tissue samples with microfluidic devices to provide a more accurate and predictive model for studying tumor microenvironments and evaluating therapeutic responses. By using human tissue, the platform more closely mimics the in vivo environment, allowing for better predictions of drug efficacy compared to traditional in vivo testing. This approach aims to reduce clinical trial failure rates by providing more reliable data early in the drug development process. The platform enables researchers to analyze drug interactions within a complex, human-relevant system.
Target Audience
The primary audience includes pharmaceutical companies, biotech firms, and academic research institutions involved in drug discovery and development, particularly in oncology.
Features
- Integration of human tissue samples with microfluidic devices
- Ex vivo platform for studying tumor microenvironments
- Evaluation of therapeutic responses in a human-relevant system
- Enhanced prediction of drug efficacy compared to in vivo testing